Sonnet Biotherapeutics Holdings Stock Performance
| SONN Stock | USD 1.27 0.04 3.05% |
The entity has a beta of 0.83, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Sonnet Biotherapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Sonnet Biotherapeutics is expected to be smaller as well. At this point, Sonnet Biotherapeutics has a negative expected return of -0.0514%. Please make sure to validate Sonnet Biotherapeutics' total risk alpha, kurtosis, as well as the relationship between the Kurtosis and price action indicator , to decide if Sonnet Biotherapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Sonnet Biotherapeutics is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
Last Split Factor 1:8 | Dividend Date 2020-04-02 | Last Split Date 2024-09-30 |
1 | Sonnet BioTherapeutics Further Expands Global Intellectual Prope | 01/28/2025 |
2 | Acquisition by Dyrness Albert D. of 8005 shares of Sonnet Biotherapeutics subject to Rule 16b-3 | 01/31/2025 |
3 | Sonnet BioTherapeutics reports wider Q1 net loss, CFO transition | 02/13/2025 |
4 | Sonnet Biotherapeutics Reports Increased Revenue and Strategic Developments - TipRanks | 02/14/2025 |
5 | Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate Platform is Available for Drug Discovery Partnerships with Potential for Producing... | 02/19/2025 |
6 | Sonnet BioTherapeutics Presents Compilation of Data Highlighting the Potential of SON-1010 as a Monotherapy or a Combination Therapy to Improve the Treatment of... | 02/26/2025 |
7 | Acquisition by Pankaj Mohan of 320135 shares of Sonnet Biotherapeutics at 1.0E-4 subject to Rule 16b-3 | 03/03/2025 |
8 | Sonnet BioTherapeutics Holdings, Inc. Short Interest Update | 03/05/2025 |
9 | Sonnet BioTherapeutics Holdings, Inc. Participates in the Virtua | 03/11/2025 |
10 | Acquisition by Susan Dexter of 14627 shares of Sonnet Biotherapeutics subject to Rule 16b-3 | 03/14/2025 |
11 | Acquisition by Susan Dexter of 63104 shares of Sonnet Biotherapeutics at 1.0E-4 subject to Rule 16b-3 | 03/18/2025 |
12 | Acquisition by Susan Dexter of 1452 shares of Sonnet Biotherapeutics at 1.0E-4 subject to Rule 16b-3 | 03/21/2025 |
13 | Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination ... | 03/26/2025 |
| Begin Period Cash Flow | 2.3 M |
Sonnet |
Sonnet Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 148.00 in Sonnet Biotherapeutics Holdings on December 28, 2024 and sell it today you would lose (17.00) from holding Sonnet Biotherapeutics Holdings or give up 11.49% of portfolio value over 90 days. Sonnet Biotherapeutics Holdings is currently does not generate positive expected returns and assumes 5.7346% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Sonnet, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Sonnet Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sonnet Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sonnet Biotherapeutics Holdings, and traders can use it to determine the average amount a Sonnet Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.009
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SONN |
Estimated Market Risk
| 5.73 actual daily | 51 51% of assets are less volatile |
Expected Return
| -0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sonnet Biotherapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sonnet Biotherapeutics by adding Sonnet Biotherapeutics to a well-diversified portfolio.
Sonnet Biotherapeutics Fundamentals Growth
Sonnet Stock prices reflect investors' perceptions of the future prospects and financial health of Sonnet Biotherapeutics, and Sonnet Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sonnet Stock performance.
| Return On Equity | -2.85 | ||||
| Return On Asset | -1.34 | ||||
| Operating Margin | (2.85) % | ||||
| Current Valuation | (673.16 K) | ||||
| Shares Outstanding | 3.07 M | ||||
| Price To Book | 1.01 X | ||||
| Price To Sales | 4.08 X | ||||
| Revenue | 18.63 K | ||||
| EBITDA | (11.85 M) | ||||
| Cash And Equivalents | 5.22 M | ||||
| Cash Per Share | 1.21 X | ||||
| Total Debt | 130.86 K | ||||
| Debt To Equity | 0.36 % | ||||
| Book Value Per Share | 1.34 X | ||||
| Cash Flow From Operations | (8.61 M) | ||||
| Earnings Per Share | (10.29) X | ||||
| Total Asset | 2.77 M | ||||
| Retained Earnings | (117.68 M) | ||||
About Sonnet Biotherapeutics Performance
By examining Sonnet Biotherapeutics' fundamental ratios, stakeholders can obtain critical insights into Sonnet Biotherapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Sonnet Biotherapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey. Sonnet BioTherapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 9 people.Things to note about Sonnet Biotherapeutics performance evaluation
Checking the ongoing alerts about Sonnet Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sonnet Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sonnet Biotherapeutics generated a negative expected return over the last 90 days | |
| Sonnet Biotherapeutics has high historical volatility and very poor performance | |
| Sonnet Biotherapeutics may become a speculative penny stock | |
| Sonnet Biotherapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 18.63 K. Net Loss for the year was (7.44 M) with loss before overhead, payroll, taxes, and interest of (351.39 K). | |
| Sonnet Biotherapeutics Holdings currently holds about 5.22 M in cash with (8.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.21. | |
| Latest headline from gurufocus.com: Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination ... |
- Analyzing Sonnet Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sonnet Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Sonnet Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sonnet Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sonnet Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sonnet Biotherapeutics' stock. These opinions can provide insight into Sonnet Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sonnet Biotherapeutics Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Pair Correlation module to compare performance and examine fundamental relationship between any two equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sonnet Biotherapeutics. If investors know Sonnet will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sonnet Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (10.29) | Revenue Per Share 0.959 | Quarterly Revenue Growth 52.688 | Return On Assets (1.34) | Return On Equity |
The market value of Sonnet Biotherapeutics is measured differently than its book value, which is the value of Sonnet that is recorded on the company's balance sheet. Investors also form their own opinion of Sonnet Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sonnet Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sonnet Biotherapeutics' market value can be influenced by many factors that don't directly affect Sonnet Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sonnet Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sonnet Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sonnet Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.